Acute effects of pharmacotherapies in blood pressure in normotensive moderate smokers

Blood Pressure

Volumn 18, Issue 5, 2009, Pages 255-260

  Martins, Luíz Cláudio ^a   Ferreira Melo, Sílvia Elaine ^a   Sabha, Maricene ^a   Coelho, Otávio Rizzi ^a   Yugar Toledo, Juan Carlos ^a   Quinaglia, Thiago ^a   Moreira, Marcos Mello ^a   Coca, Antonio ^b   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Endothelium; Hypertension; Smoking cessation; Tobacco; Vascular function

Indexed keywords

AMFEBUTAMONE; NICOTINE; PLACEBO;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; CIGARETTE SMOKING; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; HEADACHE; HEART RATE; HUMAN; MALE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TOBACCO DEPENDENCE; TREATMENT DURATION;

ADULT; BLOOD PRESSURE; BUPROPION; CROSS-OVER STUDIES; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NICOTINE; SINGLE-BLIND METHOD; SMOKING; SMOKING CESSATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 70450177643     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050903289606     Document Type: Article

References (47)

1. Gostin LO. global regulatory strategies for tobacco control. JAMA. 2007;298:2057-2059
2. Kotseva K, Wood D, De Backer g, De Bacquer D, Pyörälä K, Keil U; EUrOASPIrE Study group. Cardiovascular prevention guidelines in daily practice: A comparison of EUrOA-SPIrE I, II, and III surveys in eight European countries. Lancet. 2009;373:929-940.
3. Jain A. Treating nicotine addiction. BMJ. 2003;327:1394-1395
4. Moennikes O, vanscheeuwijck PM, Friedrichs B, Anskeit E, Patskan gJ. reduced toxicological activity of cigarette smoke by the addition of ammonia magnesium phosphate to the paper of an electrically heated cigarette: Subchronic inhalation toxicology. Inhal Toxicol. 2008;20:647-663
5. Kuper H, Adami HO, Boffetta P. Tobacco use, cancer causation and public health impact. J Intern Med. 2002;251:455-466
6. Haustein KO. What can we do in secondary prevention of cigarette smoking? Eur J Cardiovasc Prev rehabil. 2003; 10:476-485
7. Benowitz NL, Hansson A, Jacob P. 3rd Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension. 2002;39:1107-1112.
8. Lavelle C, Birek C, Scott DA. Are nicotine replacement strategies to facilitate smoking cessation safe? J Can Dent Assoc. 2003;69:592-597.
9. Bondarev ML, Bondareva TS, Young r, glennon rA. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol. 2003;474:85-93
10. Shrier M, Diaz JE, Tsarouhas N. Cardiotoxicity associated with bupropion overdose. Ann Emerg Med. 2000;35:100.
11. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris rM, Fibiger HC, et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56:395-401.
12. Britton J, Jarvis MJ. Bupropion: A new treatment for smokers. Nicotine replacement treatment should also be available on the NHS. BMJ. 2000;321:65-66.
13. gobbi g, Slater S, Boucher N, Debonnel g, Blier P. Neuro-chemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol. 2003;23:233-239.
14. glover ED, glover PN, Payne TJ. Treating nicotine dependence. Am J Med Sci. 2003;326:183-186.
15. Hurt RD, Sachs DP, glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997; 337:1195-1202
16. Tønnesen P, Tonstad S, Hjalmarson A, Lebargy F, van Spiegel PI, Hider A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion Sr for smoking cessation. J Intern Med. 2003;254:184-192. (Pubitemid 36900442)
17. Hughes Jr. Motivating and helping smokers to stop smoking. J gen Intern Med. 2003;18:1053-1057.
18. World Health Organization-International Society of Hypertension guidelines for the Management of Hypertension-guidelines Subcommittee. J Hypertens. 1999;17:151-183.
19. Jones DW, Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension. 2004;43:1-3.
20. Taylor DH Jr, Hasselblad v, Henley SJ, Thun MJ, Sloan FA. Benefts of smoking cessation for longevity. Am J Public Health. 2002;92:990-996.
21. Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med. 2008;121:(4 Suppl 1):S20-S31.
22. Benowitz NL, gourlay Sg. Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422-1431.
23. Benowitz NL, Porchet H, Sheiner L, Jacob P 3rd. Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clin Pharmacol Ther. 1988;44:23-28.
24. Cryer PE, Haymond MW, Santiago Jv, Shah SD. Norepine-phrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med. 1976;295:573-577.
25. Chalon S, Moreno H Jr, Benowitz NL, Hoffman BB, Blaschke TF. Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther. 2000;67:391-397.
26. Marano g, ramirez A, Mori I, Ferrari AU. Sympathectomy inhibits the vasoactive effects of nicotine in conscious rats. Cardiovasc res. 1999;42:201-205.
27. Grassi g, Seravalle G, Calhoun DA, Bolla GB, giannattasio C, Marabini M, et al. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation. 1994;90:248-253.
28. Moreno H Jr, Chalon S, Urae A, Tangphao O, Abiose AK, Hoffman BB, et al. Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation. Am J Physiol. 1998;275(3 Pt 2):H1040-H1045.
29. Yugar-Toledo JC, Tanus-Santos JE, Sabha M, Sousa Mg, Cittadino M, Tácito LH, et al. Uncontrolled hypertension, uncompensated type II diabetes, and smoking have different patterns of vascular dysfunction. Chest. 2004;125:823-830.
30. Macklin KD, Maus AD, Pereira EF, Albuquerque EX, Conti-Fine BM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther. 1998;287:435-439.
31. Mayhan Wg, Sharpe gM, Anding P. Agonist-induced release of nitric oxide during acute exposure to nicotine. Life Sci. 1999;65:1829-1837.
32. Sabha M, Tanus-Santos JE, Toledo JC, Cittadino M, rocha JC, Moreno H Jr. Transdermal nicotine mimics the smoking-induced endothelial dysfunction. Clin Pharmacol Ther. 2000;68:167-174.
33. Benowitz NL, Jacob P. 3rd Jones RT, rosenberg J. Interindi-vidual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther. 1982;221: 368-372.
34. Benowitz NL, Fitzgerald GA, Wilson M, zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: Comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993;22:1159-1167.
35. Tanus-Santos JE, Toledo JC, Cittadino M, Sabha M, rocha JC, Moreno H Jr. Cardiovascular effects of transdermal nicotine in mildly hypertensive smokers. Am J Hypertens. 2001;14. (7 Pt 1):610-614.
36. Parati G, Di rienzo M, Bertinieri G, Pomidossi G, Casadei R, groppelli A, et al. Evaluation of the baroreceptor-heart rate refex by 24-hour intra-arterial blood pressure monitoring in humans. Hypertension. 1988;12:214-222.
37. Tanus-Santos JE, Sampaio rC, Hyslop S, Franchini Kg, Moreno H Jr. Endothelin ET(A) receptor antagonism atten-uates the pressor effects of nicotine in rats. Eur J Pharmacol. 2000;396:33-37.
38. Fattinger K, verotta D, Benowitz NL. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol Exp Ther. 1997;281:1238-1246.
39. gerhardt U, Hans U, Hohage H. Infuence of smoking on baroreceptor function: 24 h measurements. J Hypertens. 1999;17:941-946. (Pubitemid 29322182)
40. Mancia g, groppelli A, Di rienzo M, Castiglioni P, Parati g. Smoking impairs barorefex sensitivity in humans. Am J Physiol. 1997;273. (3 Pt 2):H1555-H1560.
41. Benowitz NL, Chan K, Denaro CP, Jacob P 3rd. Stable isotope method for studying transdermal drug absorption: The nicotine patch. Clin Pharmacol Ther. 1991;50:286-293.
42. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther. 1999;288:88-92.
43. Roose SP, Dalack GW, glassman AH, Woodring S, Walsh BT, giardina Eg. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry. 1991;148:512-516.
44. Richmond R, zwar N. review of bupropion for smoking cessation. Drug Alcohol rev. 2003;22:203-220.
45. Parati g, Casadei R, groppelli A, Di rienzo M, Mancia G. Comparison of fnger and intra-arterial blood pressure monitoring at rest and during laboratory testing. Hypertension. 1989;13(6 Pt 1):647-655.
46. Benowitz NL. Basic cardiovascular research and its implications for the medicinal use of nicotine. J Am Coll Cardiol. 2003;41:497-498.
47. Zeidler R, Albermann K, Lang S. Nicotine and apoptosis. Apoptosis. 2007;12:1927-1943.